Natural Remedy app launched to support mental health

VANCOUVER, BC, August 3, 2022 /CNW/ – PanGenomic Health Inc. (“PanGenomic Health”) (CSE: NARA) is pleased to announce that its Nara app is now available for download in North America on the Apple App Store and Google Play Store. As one of from Canada A premier publicly traded benefit company, PanGenomic Health is committed to providing consumers with personalized information about evidence-based natural remedy solutions to support mental health.

“People are taking more control over their personal health decisions and want access to evidence-based information about mental health solutions delivered in a user-friendly way,” said Robert Nygren, Executive Chairman of PanGenomic Health. “With our Nara app, users can access, share and discuss trusted sources of information about mental health treatment to learn about their own use of pharmaceutical drugs and natural remedies.”

In a widely reported study published last month in Molecular psychiatry Led by researchers from University College London, UK, Italian and Swiss researchers carried out a systematic review of the evidence for the chemical imbalance theory of serotonin in depression. The researchers concluded that “This review suggests that the enormous research effort based on the serotonin hypothesis has not produced convincing evidence for a biochemical basis for depression. This is consistent with research on many other biomarkers. We suggest it’s time to acknowledge that the serotonin-based theory of depression is not empirically supported..” [See: Moncrieff, J., Cooper, R.E., Stockmann, T. et al. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry (2022). https://doi.org/10.1038/s41380-022-01661-0].

Free Nara app includes herbal library, curated articles, mental wellness tracker, community forum and access to DNA analysis reports to learn how genetics can impact on the effectiveness of natural remedy solutions.

About PanGenomic Health

PanGenomic Health Inc. is a precision health company that has developed a digital self-care platform to provide personalized, evidence-based information on natural treatments. Our initial goal is to support mental health. Saved as British Columbia Benefit Company, PanGenomic Health’s mission is to promote and improve the health and well-being of people and society by providing a technology platform that identifies herbal solutions tailored to each individual’s health profile.

For more product information, please visit www.nara.care or download the Nara app at:

Apple App store: www.apps.apple.com/us/app/care-with-nara/id1614523255
Google Play Store: www.play.google.com/store/apps/details?id=com.pgxmobileclient

This press release contains certain statements that may be considered “forward-looking statements”, including statements regarding the services to be provided by PanGenomic and the consideration to be paid to PanGenomic. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, ” believe” and similar expressions are intended to identify forward-looking statements. Although PanGenomic believes that the expectations and assumptions on which forward-looking statements are based are reasonable, undue reliance should not be placed on forward-looking statements as PanGenomic cannot guarantee that they will prove to be accurate. Because forward-looking statements address future events and conditions, they, by their very nature, involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including various risk factors discussed in PanGenomic’s disclosure documents which can be found under PanGenomic’s profile on www.sedar.com.

The Canadian Securities Exchange has neither approved nor disapproved of the information contained in this press release and accepts no responsibility for the adequacy or accuracy of this press release.

SOURCE PanGenomic Health Inc.

For further information: Jerry Lai, Investor Relations, PanGenomic Health Inc., 778 743 4642, [email protected]

Jennifer C. Burleigh